Under the skin, a tiny laboratory

EPFL scientists have developed a tiny, portable personal blood testing laboratory that sends data through mobile phone network

2013-03-20

(Press-News.org) VIDEO: EPFL scientists have developed a tiny, portable personal blood testing laboratory: a minuscule device implanted just under the skin provides an immediate analysis of substances in the body, and a...
Click here for more information.

Humans are veritable chemical factories - we manufacture thousands of substances and transport them, via our blood, throughout our bodies. Some of these substances can be used as indicators of our health status. A team of EPFL scientists has developed a tiny device that can analyze the concentration of these substances in the blood. Implanted just beneath the skin, it can detect up to five proteins and organic acids simultaneously, and then transmit the results directly to a doctor's computer. This method will allow a much more personalized level of care than traditional blood tests can provide. Health care providers will be better able to monitor patients, particularly those with chronic illness or those undergoing chemotherapy. The prototype, still in the experimental stages, has demonstrated that it can reliably detect several commonly traced substances. The research results will be published and presented March 20, 2013 in Europe's largest electronics conference, DATE 13.

Three cubic millimeters of technology

The device was developed by a team led by EPFL scientists Giovanni de Micheli and Sandro Carrara. The implant, a real gem of concentrated technology, is only a few cubic millimeters in volume but includes five sensors, a radio transmitter and a power delivery system. Outside the body, a battery patch provides 1/10 watt of power, through the patient's skin – thus there's no need to operate every time the battery needs changing.

Information is routed through a series of stages, from the patient's body to the doctor's computer screen. The implant emits radio waves over a safe frequency. The patch collects the data and transmits them via Bluetooth to a mobile phone, which then sends them to the doctor over the cellular network.

A system that can detect numerous substances

Great care was taken in developing the sensors. To capture the targeted substance in the body – such as lactate, glucose, or ATP – each sensor's surface is covered with an enzyme. "Potentially, we could detect just about anything," explains De Micheli. "But the enzymes have a limited lifespan, and we have to design them to last as long as possible." The enzymes currently being tested are good for about a month and a half; that's already long enough for many applications. "In addition, it's very easy to remove and replace the implant, since it's so small."

The electronics were a considerable challenge as well. "It was not easy to get a system like this to work on just a tenth of a watt," de Micheli explains. The researchers also struggled to design the minuscule electrical coil that receives the power from the patch.

Towards personalized chemotherapy

The implant could be particularly useful in chemotherapy applications. Currently, oncologists use occasional blood tests to evaluate their patients' tolerance to a particular treatment dosage. In these conditions, it is very difficult to administer the optimal dose. De Micheli is convinced his system will be an important step towards better, more personalized medicine. "It will allow direct and continuous monitoring based on a patient's individual tolerance, and not on age and weight charts or weekly blood tests."

In patients with chronic illness, the implants could send alerts even before symptoms emerge, and anticipate the need for medication. "In a general sense, our system has enormous potential in cases where the evolution of a pathology needs to be monitored or the tolerance to a treatment tested."

The prototype has already been tested in the laboratory for five different substances, and proved as reliable as traditional analysis methods. The project brought together eletronics experts, computer scientists, doctors and biologists from EPFL, the Istituto di Ricerca di Bellinzona, EMPA and ETHZ. It is part of the Swiss Nano-Tera program, whose goal is to encourage interdisciplinary research in the environmental and medical fields. Researchers hope the system will be commercially available within 4 years.

INFORMATION:

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

High potency statins pose significantly higher risk of kidney injury than low potency, say experts

2013-03-20

Research: Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases Editorial: Statins in acute kidney injury: friend or foe? Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalised for acute kidney injury (AKI), compared with those taking low potency statins, a paper published today on bmj.com suggests. The use of statins is often recommended to reduce the risk of cardiovascular disease among high risk patients. However, ...

Mayo Clinic neurologists present research at American Academy of Neurology Annual Meeting

2013-03-20

SAN DIEGO — Mayo Clinic neurology experts will present research findings on Parkinson's disease, Alzheimer's disease, sleep disorders, concussions, multiple sclerosis and more at the American Academy of Neurology annual meeting in San Diego, March 16. They also are available to offer expert comment on other research findings. Mayo studies being presented and their embargo times include: Cognitively normal people with high amyloid levels likelier to develop dementia EMBARGOED until Monday, March 18, 2013, 1:30 p.m. EDT People who aren't showing signs of cognitive ...

New disorder could classify millions of people as mentally ill

2013-03-20

Personal View: The new somatic symptom disorder in DSM-5 risks mislabeling many people as mentally ill Millions of people could be mislabeled as mentally ill when psychiatry's bible of diagnoses is updated in May, warns a senior doctor in this week's BMJ. The next edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) – used around the world to classify mental disorders - will include a new category of somatic symptom disorder. But Allen Frances, Chair of the current (DSM-IV) task force warns that the DSM-5 ...

Studies for approval of new drugs have insufficient patients to evaluate safety

2013-03-20

For medicines intended for chronic use, the number of patients studied before regulatory approval is insufficient to properly evaluate safety and long-term efficacy, requiring the need for new legislation, according to a study by European researchers published in this week's PLOS Medicine. Current European guidelines specify that in order to fully evaluate the safety of medicines being developed for chronic (long-term) treatment of non-life threatening diseases, at least 1000 patients must take the new drug and that 300 and 100 patients must use the drug for 6 and 12 ...

African immunization systems fall short, African experts say

2013-03-20

In Africa, issues of vaccine supply, financing, and sustainability require urgent attention if the Millennium Development Goals are to be achieved, according to African experts writing in this week's PLOS Medicine. Shingai Machingaidze, Charles Wiysonge, and Gregory Hussey from the University of Cape Town in South Africa commend African countries for their progress in immunisation programmes but infectious disease outbreaks, for example, polio and measles outbreaks, as well as high vaccine dropout rates across the region, indicate failures within the immunisation system. ...

For polar bears, it's survival of the fattest

2013-03-20

One of the most southerly populations of polar bears in the world – and the best studied – is struggling to cope with climate-induced changes to sea ice, new research reveals. Based on over 10 years' data the study, published in the British Ecological Society's Journal of Animal Ecology, sheds new light on how sea ice conditions drive polar bears' annual migration on and off the ice. Lead by Dr Seth Cherry of the University of Alberta, the team studied polar bears in western Hudson Bay, where sea ice melts completely each summer and typically re-freezes from late November ...

Caffeine 'can significantly protect against crash risk' for long distance heavy vehicle drivers

2013-03-20

Research: Use of caffeinated substances and risk of crashes in long distance drivers of commercial vehicles: case-control study Long distance commercial drivers who consume caffeinated substances such as coffee or energy drinks, to stay awake while driving, are significantly less likely to crash than those who do not, even though they drive longer distances and sleep less, finds a study published today on bmj.com. Long distance drivers routinely experience monotonous and extended driving periods in a sedentary position, which has been associated with wake time drowsiness, ...

'Kill Bill' character inspires the name of a new parasitoid wasp species

2013-03-20

Parasitoid wasps of the family Braconidae are known for their deadly reproductive habits. Most of the representatives of this group have their eggs developing in other insects and their larvae, eventually killing the respective host, or in some cases immobilizing it or causing its sterility. Three new species of the parasitoid wasp genus Cystomastacoides, recently described in the Journal of Hymenoptera Research, reflect this fatal behavior. Two of the new species were discovered in Papua New Guinea, while the third one comes from Thailand. The Thai species, Cystomastacoides ...

Max Planck Florida Institute study points to major discovery for Alzheimer's disease

2013-03-20

FLORIDA, March 19, 2013 – The Journal of Neuroscience has published a study led by researchers at the Max Planck Florida Institute for Neuroscience, the first and only U.S. extension of the prestigious Max Planck Society, that may hold a stunning breakthrough in the fight to treat Alzheimer's disease. The study potentially identifies a cause of Alzheimer's disease—based on a newly-discovered signaling pathway in cellular models of Alzheimer's disease—and opens the door for new treatments by successfully blocking this pathway. The Institute, which recently opened in December ...

First of its kind study in Canada looks at who is taking aspirin to prevent heart attack or stroke

2013-03-20

A new study out of the Faculty of Medicine & Dentistry shows a large population of healthy people are taking Aspirin to prevent cardiovascular disease, despite the fact that new literature shows it isn't as beneficial as once thought. Olga Szafran and Mike Kolber, in the Department of Family Medicine at the University of Alberta, surveyed patients over the age of 50 at two clinics in Alberta. They found that more than 40 per cent of people who don't suffer from cardiovascular disease are popping pills daily to prevent a heart attack or stroke – a practice called primary ...

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

Under the skin, a tiny laboratory

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: